On September 14, 2023 Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, reported that the company will present at the Pareto Securities Healthcare Conference, Today, September 14, at 12.55 CET (Press release, Medivir, SEP 14, 2023, View Source [SID1234635172]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CEO Jens Lindberg will give an updated presentation of the company following the recently presented promising interim results from the ongoing phase 1b/2a combination study with fostrox + Lenvima in primary liver cancer (HCC).

The presentation will be available after the meeting on Medivirs website; www.medivir.com.